[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overweight-or-obese-adults\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overweight-or-obese-adults":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,77,99,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100565284","feasibility-and-plausible-effectiveness-of-a-lifestyle-intervention-in-kidney-transplant-recipients-heal-100565284",false,"NCT06640179","Feasibility and Plausible Effectiveness of a Lifestyle Intervention in Kidney Transplant Recipients (HEAL)","Prevention of Weight Gain and Impaired Glucose Metabolism Post Kidney Transplantation: A Pilot and Feasibility Study","HEAL","Inclusion Criteria:\n\n* Receiving a kidney transplant within the prior 3-5 months, with the transplant received from a deceased donor or living donor. NOTE: The patient will be eligible for randomization at 3 months following the kidney transplant, or at a subsequent time once clearance from the kidney transplant physician is given, provided that the time does not exceed 5 months following the kidney transplant.\n* Both males and females of all race\u002Fethnic groups are eligible for participation in this study.\n* \\>=18 years of age.\n* Body mass index (BMI) \\>22 kg\u002Fm2. There is no maximal BMI provided that the weight does not exceed the weight allowance of the dual-energy x-ray absorptiometer (DXA) that is used to assess body composition (maximal weight for the DXA is 350 pounds).\n* Ability to provide informed consent prior to participation in this study.\n* Ability to provide clearance from their kidney transplant physician to engage in the diet and physical activity components of the proposed intervention and to safely complete the proposed outcome measures.\n* Ability to walk for exercise.\n\nExclusion Criteria:\n\n* Females who are pregnant, breastfeeding, or reporting a planned pregnancy during the study period. Female participants of childbearing age who are not currently taking contraceptive medication, are not post-menopausal, or have not been surgically sterilized will need to agree to use a double barrier method of contraception.\n* History of bariatric surgery.\n* Currently prescribed an anti-obesity medication.\n* Report current medical condition or treatment for a medical condition that could affect body weight. These may include the following: diabetes mellitus; hyperthyroidism; inadequately controlled hypothyroidism; chronic liver disease; cancer; gastrointestinal disorders including ulcerative colitis, Crohn's disease, or malabsorption syndromes; etc.\n* Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction, coronary artery bypass grafting or angioplasty, conditions requiring chronic anticoagulation (i.e., recent or recurrent DVT).\n* Resting systolic blood pressure of \\>=160 mmHg or resting diastolic blood pressure of \\>=100 mmHg or not on a stable medical treatment to control hypertension (stable dose is defined as the same dose and type of medication for a period of at least 6 months).\n* Eating disorders that would contraindicate modifying eating or physical activity behaviors.\n* Alcohol or substance abuse.\n* Currently treated for psychological issues (i.e., depression, bipolar disorder, etc.) that is accompanied by the following: 1) not on a stable dose of medications for treatment within the previous 12 months, or 2) hospitalized for depression within the previous 5 years.\n* Report plans to relocate to a location not accessible to the study site or having employment, personal, or travel commitments that prohibit attendance at scheduled intervention sessions or assessments.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether if it is feasible to implement a study of patients receiving kidney transplantation, to learn if these patients will complete selective outcomes measurements, and to examine if a lifestyle intervention may assist with preventing weight gain compared to standard medical care. The main questions it aims to answer are:\n\n* Is it feasible to recruit and retain patients who have undergone kidney transplantation into a study to compare standard medical care to standard medical care plus a lifestyle intervention focused on prevention of weight gain?\n* Will participants engage in the interventions and be compliant to the components of the interventions?\n* Will there be any difference between the interventions between the interventions for the occurrence of adverse events specific to kidney transplantation?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on preventing weight gain compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on body composition compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on fasting glucose compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on fasting insulin compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on insulin sensitivity compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on physical function compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on health-related quality of life compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on changes in dietary intake compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on physical activity and sedentary behavior compared to standard medical care alone?\n\nParticipants will:\n\n* Participants will continue with their standard medical care following kidney transplantation.\n* Participants only receiving standard medical care will also complete brief monitoring visits at week 6, 12, and 18.\n* Participants receiving the lifestyle intervention will attend weekly intervention sessions and will be recommended to modify their diet and physical activity behaviors in an effort to prevent weight gain.\n* Participants will complete outcome measurements as the start of the study and again after 6 months in the study.\n* After 6 months in the study, participants will also complete a brief intervention and answer other questions about their experience in the study.",[27,28,29],"Kidney Transplant","Overweight or Obese Adults","Glucose Control",[31,32,33,34,35],"kidney transplant","overweight","obesity","glucose control","weight control","RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2024-12-17",{"date":44,"type":21},"2027-03-01",{"name":46,"class":47},"University of Kansas Medical Center","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100623672","phase-1-study-of-alv-100-to-assess-safety-tolerability-and-pkpd-in-overweightobese-participants-with-or-without-t2d-100623672","NCT07399678","Study of ALV-100 to Assess Safety, Tolerability, and PK\u002FPD in Overweight\u002FObese Participants With or Without T2D","A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALV-100 in Participants With Overweight or Obesity With or Without Type 2 Diabetes","Inclusion Criteria:\n\nFor Part A and B\n\n* Adult male and female participants, aged 18 to 65 years, inclusive, at the time of signing the informed consent form\n* Body mass index between 27.0 to 39.9 kg\u002Fm2 at Screening, both inclusive; overweight should be due to excess adipose tissue, as judged by the Investigator.\n* Have a stable body weight (\\\u003C 5.0 kg\u002F11 lbs self-reported change) within 90 days prior to Screening\n* Females must be surgically sterile (by means of bilateral salpingectomy, hysterectomy or bilateral oophorectomy) or be post-menopausal (defined as spontaneous cessation of menses for at least 1 year prior to Screening). Females who are post-menopausal and \\\u003C 55 years must have a follicle-stimulating hormone level \\> 40 IU\u002FL at Screening.\n* Males with female partners of child-bearing potential must be willing to practice abstinence or must agree to use condom as contraception throughout the duration of the study. This criterion may be waived for male participants who have had a documented successful vasectomy \\> 6 months before signing the ICF.\n\nFor Part B only\n\n* Diagnosis of Type 2 Diabetes for at least 180 days prior to Screening.\n* Glycemic control managed by diet and exercise alone or by stable treatment with metformin and\u002For sodium-glucose cotransporter 2 inhibitors (SGLT-2i), with no dose changes within 3 months prior to Screening.\n* Hemoglobin A1c (HbA1c) between 7.0 % and 9.0% (equivalent to 53-75 mmol\u002Fmol), both inclusive, at Screening.\n\nExclusion Criteria:\n\nFor Part A and B\n\n* History or presence of any clinically relevant respiratory, metabolic (including dyslipidemia, however mild dyslipidemia, defined as screening total cholesterol below or equal to 302 mg\u002FdL (7.8 mmol\u002FL) and\u002For screening triglyceride below 300 mg\u002FdL (3.39 mmol\u002FL) is accepted), renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with type 2 diabetes in Part B) at the discretion of the Investigator.\n* Participants with a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 or a personal history of nonfamilial medullary thyroid carcinoma.\n* Current or history of chronic or acute pancreatitis.\n* Obesity caused by known endocrinologic disorders (e.g., Cushing syndrome) or monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndrome).\n* History of major depressive disorder or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or anxiety disorder).\n* Lifetime history of a suicide attempt or of any suicidal behavior by endorsement of (answered yes to) any of the items in the suicidal behavior section on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening.\n* Systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at Screening.\n* History of or current cardiovascular disease, including but not limited to stable and unstable angina, myocardial infarction, congestive heart failure, transient ischemic attack, stroke, clinically significant arrhythmias and conduction disorders or venous thromboembolism.\n\nPart A only\n\n• History or clinical evidence of Type 1 or Type 2 diabetes mellitus, including HbA1c ≥ 6.5% and\u002For a fasting plasma glucose (FPG) ≥ 126 mg\u002FdL (7.0 mmol\u002FL) at Screening (female participants with a history of gestational diabetes are allowed).\n\nPart B only\n\n* Fasting plasma glucose (FPG) \\> 270 mg\u002FdL (15.0 mmol\u002FL) at Screening.\n* Proliferative retinopathy or maculopathy as judged by the investigator based on a recent (within1.5 years from Screening) ophthalmologic examination.\n* Severe neuropathy as judged by the investigator.\n* Advanced nephropathy (defined as albuminuria ≥ 300 mg\u002Fg).\n* History of severe hypoglycemia or hypoglycemic unawareness as judged by the investigator.","65 Years",{"count":58,"type":21},180,[60],"PHASE1","A Study of ALV-100 to Assess Safety, Tolerability, and PK\u002FPD in Overweight\u002FObese Participants with or without Type 2 Diabetes",[28,63],"Overweight or Obese, Type 2 Diabetes",[65],"Overweight, Obese, Obesity, Type 2 Diabetes, Weight loss","2026-05-20",{"date":68,"type":40},"2026-05-22",{"date":70,"type":40},"2025-12-29",{"date":72,"type":21},"2027-09",{"name":74,"class":75},"Alveus Therapeutics, Inc.","INDUSTRY",2,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100605510","time-restricted-eating-for-weight-loss-maintenance-100605510","NCT07163455","Time-Restricted Eating for Weight-Loss Maintenance","Time-Restricted Eating (10-Hour Window) for Weight-Loss Maintenance in Adults With Recent Intentional Weight Loss: A Multicenter, 12-Month Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants who meet all the following conditions will be included in the trial:\n\n  1. BMI ≥ 28.0 kg\u002Fm², or BMI between 24.0-27.9 kg\u002Fm² with at least one weight-related comorbidity.\n  2. Age: 18-65 years.\n  3. Weight Loss Plan: Willing to undergo a structured weight-loss program.\n\nExclusion Criteria:\n\n* Participants who meet any of the following conditions will be excluded from the trial:\n\n  1. Infectious Diseases: History of HIV\u002FAIDS, active hepatitis B\u002FC, or active tuberculosis.\n  2. Malignancy: History of any malignancy.\n  3. Organ Dysfunction:Severe hepatic impairment.Chronic kidney disease.\n  4. Cardiovascular\u002FCerebrovascular Events: History of angina, myocardial infarction, or stroke within the past 6 months.\n  5. Gastrointestinal Conditions:Severe gastrointestinal diseases (e.g., inflammatory bowel disease).Gastrointestinal surgery within the past 12 months.\n  6. Endocrine Disorders:Cushing's syndrome, hypothyroidism, acromegaly, or hypothalamic obesity.\n  7. Medications: Use of drugs affecting weight\u002Fenergy balance (e.g., antipsychotics, weight-loss medications) within the past 6 months.\n  8. Pregnancy\u002FLactation: Currently pregnant, planning pregnancy, or breastfeeding.\n  9. Compliance Issues: Inability to complete the study (due to health, immigration, or other reasons).\n  10. Informed Consent: Unwilling or unable to provide informed consent.\n  11. Weight Stability: \\>5% change in body weight within the past 6 months.\n  12. Individuals unable to use or operate a smartphone",{"count":85,"type":21},500,[24],"Weight regain after intentional short-term weight loss is a common challenge. It often undermines the long-term benefits of obesity treatment. This study is a multi-center 2-arm randomized controlled trial across six regions in China, specifically targeting overweight or obese adults who have recently achieved a short-term weight reduction (≥5% of body weight). The trial will evaluate whether a 10-hour daily Time-Restricted Eating (TRE) regimen can more effectively prevent weight regain compared to standard weight maintenance counseling alone. Both the intervention and control groups will receive the same frequency and intensity of nutritional counseling for weight maintenance; the only difference is that the TRE group will be instructed to confine their daily eating to a self-selected 10-hour window, while the control group has no eating window restriction. In addition to the primary outcome of weight regain, the study will explore potential mechanisms underlying the effects of TRE and assess secondary outcomes including changes in body composition, metabolic health, and quality of life.\n\nThis study recruits participants from six distinct regions across Eastern, Western, Southern, Northern, and Central China to enhance national representativeness. The study is divided into two phases: the first phase is a 2-month weight loss run-in phase (the screening phase), during which participants will receive standardized lifestyle and diet guidance from trained dietitians. Those who achieve at least a 5% loss of initial body weight by the end of this phase-and maintain a stable weight for approximately three weeks-will proceed to the second phase. In the second phase, participants will be randomly assigned to one of two arms for a 12-month weight maintenance intervention. The Control Arm will receive periodic weight-management nutritional counseling without any eating time restriction, while the TRE Intervention Arm will receive the same guidance plus instructions to follow a daily 10-hour time-restricted eating schedule. This design ensures both groups receive equivalent dietary and lifestyle support, with TRE as the key differential strategy. Following the 12-month intervention phase, participants will be followed for an additional 12 months (without active intervention) to observe longer-term weight outcomes.\n\nData will be collected at multiple time points: baseline (before the weight loss phase), 2 months (end of the weight loss phase and prior to the start of the maintenance phase), 5 months, 8 months, 14 months (end of the weight maintenance phase), as well as 20 months and 26 months (during the post-intervention follow-up). Key outcomes include changes in body weight (to assess weight regain or maintenance), body composition, metabolic health indicators (e.g. blood glucose, lipids), and quality of life measures. To monitor dietary behaviors, participants will be asked to upload meal photos via a designated mobile application with automatic time-stamping, which will be used to assess eating timing and adherence to the prescribed eating window. Body weight will be measured once weekly using Bluetooth-enabled smart scales. To explore potential mechanisms of action, biospecimens (blood and stool) will be collected at baseline, 2 months, 8 months, and 14 months for analysis. In addition, Continuous Glucose Monitoring (CGM) will be performed in a randomly selected subsample of 200 participants (100 from each group) using a standardized device for 14 consecutive days at months 2, 8, and 14. These data will be used to evaluate glycemic stability and adherence to the assigned eating window. Real-time CGM readings will not be disclosed to participants and will not be used to guide individual-level interventions.",[28],"2026-05-18",{"date":91,"type":40},"2026-05-19",{"date":93,"type":40},"2026-01-26",{"date":95,"type":21},"2028-07",{"name":97,"class":47},"Harbin Medical University",10,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":116,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":48},"100592090","energy2mob-study-obesity-management-in-bergued-100592090","NCT06988904","ENERGY2MOB STUDY: OBESITY MANAGEMENT IN BERGUEDÀ","EFFECTIVENESS OF THE GROUP-BASED NUTRITION EDUCATION PROGRAMME FOR OBESITY MANAGEMENT IN BERGUEDÀ: A RANDOMISED CLINICAL TRIAL. ENERGY2MOB STUDY","ENERGY2MOB","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* Overweight (BMI 27-30 kg\u002Fm²) or obesity (BMI 30-40 kg\u002Fm²)\n* Availability to attend at least 80% (6 out of 8) of the group sessions\n\nExclusion Criteria:\n\n* Significant language barriers (unable to communicate in Catalan or Spanish)\n* Previous bariatric surgery\n* Moderate to severe cognitive impairment\n* Severe psychiatric disorders preventing participation in group sessions",{"count":108,"type":21},136,[24],"Background: Obesity is a prevalent multifactorial disease worldwide and has become a significant public health concern. The latest data from the 2022 Catalonia Health Survey show that 56.2% of men and 43.7% of women are overweight or obese, and 39% of children aged 6 to 12 years have excess weight. Excess adiposity poses a health risk as it is associated with various chronic diseases such as type 2 diabetes mellitus, hypertension, and dyslipidaemia, all of which affect quality of life and increase mortality risk.\n\nHypothesis: The Energy2MOB obesity management programme in Berguedà is a group-based intervention incorporating nutrition education and physical activity. It aims to reduce excess body weight and the risk of chronic diseases, including type 2 diabetes mellitus, dyslipidaemia, and hypertension, through a multicomponent approach that enhances dietary habits, physical activity, and emotional eating regulation.\n\nObjectives\n\n* Assess the effectiveness of the Energy2MOB programme in reducing body weight by 5-10% among adults with obesity in the Berguedà health region.\n* Measure lifestyle modifications, including dietary habits, physical activity, and emotional eating.\n\nMethodology: A randomised clinical trial with two groups (control and intervention) over one year, including individuals aged 18-65 years in the Berguedà health region with overweight grade II (BMI 27-30 kg\u002Fm²) or obesity (BMI 30-40 kg\u002Fm²). Exclusion criteria include significant language barriers, previous bariatric surgery, moderate to severe cognitive impairment, and severe psychiatric disorders preventing participation in sessions. Participants must attend at least 80% of the programme.\n\nMeasurements\n\n* Sociodemographic factors: sex, age, education level, marital status, employment status.\n* Lifestyle factors: alcohol and tobacco use, dietary habits, physical activity, emotional eating, health-related quality of life.\n* Anthropometric parameters: body weight, height, BMI, waist circumference.\n* Blood pressure, medication use, biochemical parameters (fasting glucose, glycated haemoglobin, lipid profile, liver and kidney function markers, C-reactive protein).\n\nStatistical Analysis: Accepting an alpha risk of 0.05 and a statistical power above 0.8 in a bilateral contrast, 68 subjects per group are required to detect a difference of at least 2.5 kg. A common standard deviation of 4.77 is assumed, with an estimated 15% dropout rate. Sample size calculations were performed using GRANMO version 8.0 (https:\u002F\u002Fwww.datarus.eu\u002Fca\u002Faplications\u002Fgranmo\u002F; consulted in November 2024).\n\nExpected Outcomes, Applicability, and Relevance: This study aims to generate scientific evidence on the effectiveness of multicomponent group-based interventions focused on improving nutrition, physical activity, and psychological well-being in obesity and chronic disease management. It seeks to create an environment that facilitates behavioural changes, leading to weight reduction and improved quality of life. The findings will also contribute to the development of a practical guide for addressing excess weight in primary healthcare settings.\n\nKeywords (maximum 6): Adult obesity, primary health care, group interventions, dietary interventions, multicomponent interventions, Mediterranean diet.",[112,28,113,114,115],"Mediterranean Diet","Exercise Therapy","Cardiovascular Diseases","Psychological Well Being",[117,118,119,120],"obesity and overweight","primary health care","Mediterranean diet","dietary interventions","NOT_YET_RECRUITING","2025-05-22",{"date":124,"type":40},"2025-05-25",{"date":126,"type":21},"2025-06-07",{"date":128,"type":21},"2026-03-07",{"name":130,"class":47},"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":138,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":48},"100573117","the-6-minute-pegboard-and-ring-test-in-overweight-and-obese-individuals-100573117","NCT06742112","The 6-minute Pegboard and Ring Test in Overweight and Obese Individuals","Validity and Reliability of the 6-minute Pegboard and Ring Test in Assessing Upper Extremity Function in Overweight and Obese Individuals","Inclusion Criteria:\n\n* Body mass index ≥ 25 kg\u002Fm2\n* Volunteering for the study\n\nExclusion Criteria:\n\n* Having uncontrolled hypertension, diabetes mellitus\n* Having comorbidities that may affect physical functions\n* Failure to cooperate with tests to be performed\n* Liver disease, kidney disease, cancer, lung diseases and serious cardiomyopathies, neurological diseases\n* Pregnancy\n* Having a history of bariatric surgery\n* Presence of contraindications to exercise testing",{"count":139,"type":21},24,"OBSERVATIONAL","The aim of our study is to investigate the validity and reliability of the 6-minute pegboard and ring test in overweight and obese individuals.",[28],"2024-12-16",{"date":145,"type":40},"2024-12-19",{"date":147,"type":40},"2024-12-11",{"date":149,"type":21},"2025-12",{"name":151,"class":47},"Kirsehir Ahi Evran Universitesi"]